This study aimed to carry out the preclinical studies of 89ZrZr-DFO-Bevacizumab. The radiolabeled compound was prepared with radiochemical purity >99% (ITLC), and a specific activity of 74 GBq/g. Cellular studies indicated the great capability of 89ZrZr-DFO-Bevacizumab for binding to SKOV3 cell lines. High accumulation was observed in the tumor. The liver and spleen received the highest absorbed dose with 1.12 and 0.72 mGy/MBq, respectively. This radiopharmaceutical can be considered as a suitable PET agent for VEGF-expressing ovarian cancer imaging. •89ZrZr-Bevacizumab was prepared with RCP >99% and specific activity of 74 GBq/g.•89Zr was produced by 89Y(p,n)89Zr reaction using a 30 MeV cyclotron.•Cellular studies indicated great capability of compound for binding to SKOV3 cells.•High accumulation of complex was observed in tumor sites of tumor-bearing nude mice.•Liver received the highest absorbed dose with 1.12 mGy/MBq.